Editorial Comment on: Vaccine Therapy in Patients with Renal Cell Carcinoma

Abstract

come of a clinical phase I/II trial in patients with metastatic renal cell carcinoma. Hum Gene Ther 2003;14:483– 94. [33] Arroyo JC, Gabilondo F, Llorente L, Meraz-Rios MA, Sanchez-TorresC. Immune response induced invitro by CD16 and CD16 monocyte-derived dendritic cells in patients with metastatic renal cell carcinoma treated with dendritic cell vaccines. J Clin Immunol 2004;24:86–96. [34] Pandha HS, John RJ, Hutchinson J, et al. Dendritic cell immunotherapy for urological cancers using cryopreserved allogeneic tumour lysate-pulsed cells: a phase I/ II study. BJU Int 2004;94:412–8. [35] Avigan D, Vasir B, Gong J, et al. Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses. Clin Cancer Res 2004;10:4699–708. [36] Barbuto JA, Ensina LF, Neves AR, et al. Dendritic celltumor cell hybrid vaccination for metastatic cancer. Cancer Immunol Immunother 2004;53:1111–8. [37] Dannull J, Su Z, Rizzieri D, et al. Enhancement of vaccinemediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 2005;115:3623– 33. [38] Holtl L, Ramoner R, Zelle-Rieser C, et al. Allogeneic dendritic cell vaccination against metastatic renal cell carcinoma with or without cyclophosphamide. Cancer Immunol Immunother 2005;54:663–70. [39] Wierecky J, Muller MR, Wirths S, et al. Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients. Cancer Res 2006;66:5910–8. [40] Bleumer I, Tiemessen DM, Oosterwijk-Wakka JC, et al. Preliminary analysis of patients with progressive renal cell carcinoma vaccinated with CA9-peptide-pulsed mature dendritic cells. J Immunother 2007;30:116–22. [41] Matsumoto A, Haraguchi K, Takahashi T, et al. Immunotherapy against metastatic renal cell carcinoma with mature dendritic cells. Int J Urol 2007;14:277–83. [42] Kim JH, Lee Y, Bae YS, et al. Phase I/II study of immunotherapy using autologous tumor lysate-pulsed dendritic cells in patients with metastatic renal cell carcinoma. Clin Immunol 2007;125:257–67. [43] Avigan DE, Vasir B, George DJ, et al. Phase I/II study of vaccination with electrofused allogeneic dendritic cells/ autologous tumor-derived cells in patients with stage IV renal cell carcinoma. J Immunother 2007;30:749–61.